Literature DB >> 15911795

Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects.

C Enzinger1, F Fazekas, P M Matthews, S Ropele, H Schmidt, S Smith, R Schmidt.   

Abstract

OBJECTIVES: To determine the rate of brain atrophy in neurologically asymptomatic elderly and to investigate the impact of baseline variables including conventional cerebrovascular risk factors, APOE epsilon4, and white matter hyperintensity (WMH) on its progression.
METHODS: We assessed the brain parenchymal fraction at baseline and subsequent annual brain volume changes over 6 years for 201 participants (F/M = 96/105; 59.8 +/- 5.9 years) in the Austrian Stroke Prevention Study from 1.5-T MRI scans using SIENA (structural image evaluation using normalization of atrophy)/SIENAX (an adaptation of SIENA for cross-sectional measurement)(www.fmrib.ox.ac.uk/fsl). Hypertension, cardiac disease, diabetes mellitus, smoking, and regular alcohol intake were present in 64 (31.8%), 60 (29.9%), 5 (2.5%), 70 (39.3%), and 40 (20.7%) subjects, respectively. Plasma levels of fasting glucose (93.7 +/- 18.6 mg/dL), glycated hemoglobin A (HbA1c; 5.6 +/- 0.7%), total cholesterol (228.3 +/- 40.3 mg/dL), and triglycerides (127.0 +/- 75.2 mg/dL) were determined. WMH was rated as absent (n = 56), punctate (n = 120), early confluent (n = 14), and confluent (n = 11).
RESULTS: The baseline brain parenchymal fraction of the entire cohort was 0.80 +/- 0.02 with a mean annual brain volume change of -0.40 +/- 0.29%. Univariate analysis demonstrated a higher rate of brain atrophy in older subjects (p = 0.0001), in those with higher HbA1c (p = 0.0001), higher body mass index (p = 0.02), high alcohol intake (p = 0.04), severe WMH (p = 0.03), and in APOE epsilon4 carriers (p = 0.07). Multivariate analysis suggested that baseline brain parenchymal fraction, HbA1c, and WMH score explain a major proportion of variance in the rates of brain atrophy in the cohort (corrected R2 = 0.27; p = 0.0001).
CONCLUSIONS: Neurologically asymptomatic elderly experience continuing brain volume loss, which appears to accelerate with age. Glycated hemoglobin A (HbA1c) was identified as a risk factor for a greater rate of brain atrophy. Clustering of factors associated with the so-called metabolic syndrome in subjects with high HbA1c suggests a link between this syndrome and late-life brain tissue loss.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15911795     DOI: 10.1212/01.WNL.0000161871.83614.BB

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  136 in total

Review 1.  Patterns of compensation and vulnerability in normal subjects at risk of Alzheimer's disease.

Authors:  Oscar L Lopez; James T Becker; Lewis H Kuller
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

2.  White matter lesions and brain gray matter volume in cognitively normal elders.

Authors:  Cyrus A Raji; Oscar L Lopez; Lewis H Kuller; Owen T Carmichael; William T Longstreth; H Michael Gach; John Boardman; Charles B Bernick; Paul M Thompson; James T Becker
Journal:  Neurobiol Aging       Date:  2011-09-23       Impact factor: 4.673

3.  Metabolic syndrome and localization of white matter hyperintensities in the elderly population.

Authors:  Florence Portet; Adam M Brickman; Yaakov Stern; Nikolaos Scarmeas; Jordan Muraskin; Frank A Provenzano; Claudine Berr; Alain Bonafé; Sylvaine Artero; Karen Ritchie; Tasnime N Akbaraly
Journal:  Alzheimers Dement       Date:  2012-06-06       Impact factor: 21.566

4.  Thickness of the human cerebral cortex is associated with metrics of cerebrovascular health in a normative sample of community dwelling older adults.

Authors:  Elizabeth C Leritz; David H Salat; Victoria J Williams; David M Schnyer; James L Rudolph; Lewis Lipsitz; Bruce Fischl; Regina E McGlinchey; William P Milberg
Journal:  Neuroimage       Date:  2010-10-28       Impact factor: 6.556

Review 5.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Authors:  Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

Review 6.  Multimodality Review of Amyloid-related Diseases of the Central Nervous System.

Authors:  Michelle M Miller-Thomas; Adam L Sipe; Tammie L S Benzinger; Jonathan McConathy; Sarah Connolly; Katherine E Schwetye
Journal:  Radiographics       Date:  2016 Jul-Aug       Impact factor: 5.333

Review 7.  Type 2 diabetes and risk of cognitive impairment and dementia.

Authors:  Rachel A Whitmer
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

8.  A spectrum of contributions of type 2 diabetes and related metabolic characteristics to dementia.

Authors:  Ramit Ravona-Springer; Michal Schnaider Beeri
Journal:  Eur Neuropsychopharmacol       Date:  2014-12       Impact factor: 4.600

9.  Basal ganglia morphology links the metabolic syndrome and depressive symptoms.

Authors:  Ikechukwu C Onyewuenyi; Matthew F Muldoon; Israel C Christie; Kirk I Erickson; Peter J Gianaros
Journal:  Physiol Behav       Date:  2013-10-04

Review 10.  Bypassing TBI: Metabolic Surgery and the Link between Obesity and Traumatic Brain Injury-a Review.

Authors:  T W McGlennon; J N Buchwald; Walter J Pories; Fang Yu; Arthur Roberts; Eric P Ahnfeldt; Rukmini Menon; Henry Buchwald
Journal:  Obes Surg       Date:  2020-10-30       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.